US EditionWorld's first jab to stop skin cancer being tested in UK patients
- A personalized mRNA cancer jab is being tested in British patients for melanoma, with potential to target bladder, lung, and kidney cancer.
- In a trial, the jab reduced the risk of cancer recurrence in melanoma patients, leading to a final trial launch.
- The therapy involves DNA sequencing of a tumor sample and artificial intelligence, showing promising results for high-risk melanoma patients.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
4
Center
5
Right
3
In the corona pandemic, mRNA vaccination becomes a game-changer. Now, with the same technology, another disease could be combated: skin cancer. Worldwide, the new immunotherapy is now to be tested on hundreds of patients. The first shot gets a Brit.
A trial is underway in the United Kingdom to test the first personalized mRNA vaccine against melanoma, designed to adapt to the unique genetic signature of each tumor
Coverage Details
Total News Sources20
Leaning Left4Leaning Right3Center5Last UpdatedBias Distribution42% Center
Bias Distribution
- 42% of the sources are Center
42% Center
L 33%
C 42%
R 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
